PL3045471T3 - Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację - Google Patents

Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację

Info

Publication number
PL3045471T3
PL3045471T3 PL16158141T PL16158141T PL3045471T3 PL 3045471 T3 PL3045471 T3 PL 3045471T3 PL 16158141 T PL16158141 T PL 16158141T PL 16158141 T PL16158141 T PL 16158141T PL 3045471 T3 PL3045471 T3 PL 3045471T3
Authority
PL
Poland
Prior art keywords
alpha
sialylation
recombinant fsh
fsh including
including alpha
Prior art date
Application number
PL16158141T
Other languages
English (en)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3045471(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of PL3045471T3 publication Critical patent/PL3045471T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL16158141T 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację PL3045471T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25
EP13193214.7A EP2722339A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
EP09733497.3A EP2268666B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
EP16158141.8A EP3045471B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (1)

Publication Number Publication Date
PL3045471T3 true PL3045471T3 (pl) 2017-10-31

Family

ID=39717519

Family Applications (4)

Application Number Title Priority Date Filing Date
PL16194925T PL3144318T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh obejmujący alfa 2,3- oraz alfa 2,6-sialilację
PL09733497T PL2268666T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację
PL14178729T PL2808340T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację
PL16158141T PL3045471T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PL16194925T PL3144318T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh obejmujący alfa 2,3- oraz alfa 2,6-sialilację
PL09733497T PL2268666T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację
PL14178729T PL2808340T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację

Country Status (29)

Country Link
US (5) US8951967B2 (pl)
EP (7) EP2808340B1 (pl)
JP (7) JP2011519359A (pl)
KR (5) KR20160056960A (pl)
CN (3) CN105906702A (pl)
AR (1) AR071479A1 (pl)
AU (5) AU2009237479B2 (pl)
BR (1) BRPI0910461B8 (pl)
CA (1) CA2725257A1 (pl)
CY (1) CY1115413T1 (pl)
DK (4) DK3144318T3 (pl)
ES (3) ES2610277T3 (pl)
FR (1) FR17C1020I2 (pl)
HK (2) HK1146284A1 (pl)
HR (3) HRP20140535T1 (pl)
HU (5) HUE033830T2 (pl)
IL (2) IL208538A (pl)
LT (4) LT3045471T (pl)
MX (3) MX2010011343A (pl)
NO (2) NO2017025I1 (pl)
NZ (1) NZ588381A (pl)
PL (4) PL3144318T3 (pl)
PT (4) PT3144318T (pl)
RU (3) RU2537268C2 (pl)
SA (1) SA109300228B1 (pl)
SI (4) SI2268666T1 (pl)
TW (1) TWI488640B (pl)
WO (1) WO2009127826A1 (pl)
ZA (1) ZA201007373B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
HUE025514T2 (en) 2010-09-29 2016-02-29 Ferring Bv Preparation for use in treating infertility
US20130224797A1 (en) 2010-10-15 2013-08-29 Jcr Pharmaceuticals Co., Ltd. Method for producing glycoprotein having mannose residue as non-reducing end of sugar chain
JP6087338B2 (ja) * 2011-03-31 2017-03-01 フェリング ベスローテン フェンノートシャップ 医薬製剤
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
US9657310B2 (en) * 2012-04-27 2017-05-23 Jcr Pharmaceuticals Co., Ltd. Expression vector
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) * 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｍｐ依存性シアリダーゼ活性
WO2016166288A1 (en) 2015-04-17 2016-10-20 Ferring B.V. Composition for treatment of infertility
AU2016282916B2 (en) 2015-06-26 2022-01-20 Ferring B.V. Methods of purification and/or viral inactivation
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
CN111050787A (zh) 2017-09-01 2020-04-21 辉凌公司 用于受控的卵巢刺激的组合物
CN112088011A (zh) 2018-04-30 2020-12-15 辉凌公司 用于受控的卵巢刺激的组合物
TW202027780A (zh) 2018-10-17 2020-08-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
WO2021081670A1 (en) * 2019-11-01 2021-05-06 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
WO2023186331A1 (en) 2022-04-01 2023-10-05 Ferring B.V. Mixed protocol for treatment of infertility
WO2023227761A1 (en) 2022-05-26 2023-11-30 Ferring B.V. Compositions and methods for treatment of infertility in males
WO2024008971A1 (en) 2022-07-08 2024-01-11 Ferring B.V. Compositions and methods for intrauterine insemination (iui)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
EP0833934B2 (en) 1995-06-15 2012-08-15 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
IL130964A0 (en) 1997-01-16 2001-01-28 Cytel Corp Practical in vitro sialylation of recombinant glycoproteins
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
BR0010709B1 (pt) 1999-05-07 2011-11-29 uso de lh para a produção de um medicamento para induzir a paucifoliculogênese ou unifoliculogênese em mulheres anovulatórias.
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
US20050085412A1 (en) * 2001-10-22 2005-04-21 Applied Research Systems Ars Holding N.V. Gonadotrophins for folliculogenesis
CA2465007C (en) 2001-10-29 2012-01-17 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
EP1465987B1 (en) 2001-12-07 2008-01-23 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
WO2005056760A2 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
ATE476666T1 (de) 2004-02-04 2010-08-15 Centre Nat Rech Scient Verfahren zur identifizierung von glykoformspezifischen antikörpern
US8609370B2 (en) * 2004-02-13 2013-12-17 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
US8790322B2 (en) 2010-08-03 2014-07-29 King Saud University Stoma coat
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
HUE025514T2 (en) 2010-09-29 2016-02-29 Ferring Bv Preparation for use in treating infertility
JP6087338B2 (ja) 2011-03-31 2017-03-01 フェリング ベスローテン フェンノートシャップ 医薬製剤
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
SG11201608132UA (en) 2014-04-18 2016-11-29 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Also Published As

Publication number Publication date
RU2010141908A (ru) 2012-05-27
RU2014141994A (ru) 2016-05-10
US10995128B2 (en) 2021-05-04
EP3098234A1 (en) 2016-11-30
KR20180095140A (ko) 2018-08-24
MX348622B (es) 2017-06-22
BRPI0910461A2 (pt) 2018-03-27
AU2014203277A1 (en) 2014-07-24
ES2629392T3 (es) 2017-08-09
HUS1700036I1 (hu) 2017-10-30
FR17C1020I2 (fr) 2020-04-10
DK3144318T3 (da) 2020-12-07
KR101622944B1 (ko) 2016-05-23
SI2808340T1 (sl) 2016-12-30
EP3144318B1 (en) 2020-09-23
AU2009237479B2 (en) 2014-05-15
RU2014141994A3 (pl) 2018-05-28
FR17C1020I1 (pl) 2020-04-10
HUE033830T2 (en) 2018-01-29
BRPI0910461A8 (pt) 2018-10-16
HRP20161520T1 (hr) 2016-12-30
PL2268666T3 (pl) 2014-08-29
US11952407B2 (en) 2024-04-09
IL208538A (en) 2014-03-31
ZA201007373B (en) 2011-06-29
AU2017225020A1 (en) 2017-09-28
AU2017204258A1 (en) 2017-07-20
TW200948378A (en) 2009-12-01
HUE030652T2 (en) 2017-05-29
KR20160056960A (ko) 2016-05-20
RU2537268C2 (ru) 2014-12-27
PT3045471T (pt) 2017-06-14
US20160347811A1 (en) 2016-12-01
NO2017050I1 (no) 2017-09-28
JP2011519359A (ja) 2011-07-07
PL3144318T3 (pl) 2021-02-08
AU2017204258B2 (en) 2017-08-17
EP2808340B1 (en) 2016-08-17
EP2268666B1 (en) 2014-03-12
AR071479A1 (es) 2010-06-23
HUE030652T4 (en) 2017-09-28
JP6486310B2 (ja) 2019-03-20
KR20110005863A (ko) 2011-01-19
IL230571A (en) 2015-11-30
RU2682270C2 (ru) 2019-03-18
KR102108377B1 (ko) 2020-05-08
PT3144318T (pt) 2020-11-04
TWI488640B (zh) 2015-06-21
KR20170110741A (ko) 2017-10-11
EP2808340A1 (en) 2014-12-03
US8951967B2 (en) 2015-02-10
US20150065695A1 (en) 2015-03-05
AU2017225020B2 (en) 2019-11-14
JP6762916B2 (ja) 2020-09-30
SI3045471T1 (sl) 2017-07-31
MX355457B (es) 2018-04-19
BRPI0910461B8 (pt) 2021-05-25
HK1146284A1 (en) 2011-05-20
MX2010011343A (es) 2011-01-20
CY1115413T1 (el) 2017-01-04
DK3045471T3 (en) 2017-06-26
LTPA2017029I1 (lt) 2017-10-10
LTPA2017018I1 (lt) 2017-06-26
NO2017025I1 (no) 2017-06-06
AU2017204259A1 (en) 2017-07-20
US20110105398A1 (en) 2011-05-05
PT2808340T (pt) 2016-11-21
AU2009237479A1 (en) 2009-10-22
ES2468318T3 (es) 2014-06-16
US9546204B2 (en) 2017-01-17
BRPI0910461B1 (pt) 2021-02-23
EP2268666A1 (en) 2011-01-05
DK2268666T3 (da) 2014-05-12
HUS1700025I1 (hu) 2017-06-28
CN105906703A (zh) 2016-08-31
DK2808340T3 (en) 2016-12-05
EP4015527A1 (en) 2022-06-22
HK1199039A1 (en) 2015-06-19
US20180079794A1 (en) 2018-03-22
US9771407B2 (en) 2017-09-26
SI2268666T1 (sl) 2014-07-31
CN102066414A (zh) 2011-05-18
SI3144318T1 (sl) 2020-12-31
EP2722339A1 (en) 2014-04-23
EP3045471A1 (en) 2016-07-20
WO2009127826A1 (en) 2009-10-22
JP2018021037A (ja) 2018-02-08
CN105906702A (zh) 2016-08-31
LT3045471T (lt) 2017-07-10
HRP20170958T1 (hr) 2017-09-22
JP2017060476A (ja) 2017-03-30
HUS1700024I1 (hu) 2017-06-28
JP7316905B2 (ja) 2023-07-28
CA2725257A1 (en) 2009-10-22
JP2024038000A (ja) 2024-03-19
IL208538A0 (en) 2010-12-30
JP2015120696A (ja) 2015-07-02
EP3045471B1 (en) 2017-03-29
EP3144318A1 (en) 2017-03-22
JP2022031652A (ja) 2022-02-22
PL2808340T3 (pl) 2017-02-28
LT2808340T (lt) 2016-11-10
RU2745557C1 (ru) 2021-03-29
AU2017204259B2 (en) 2017-08-17
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
PT2268666E (pt) 2014-06-25
SA109300228B1 (ar) 2014-04-08
US20210332099A1 (en) 2021-10-28
RU2745557C3 (ru) 2021-12-10
NZ588381A (en) 2012-05-25
AU2014203277C1 (en) 2017-07-27
KR20190092608A (ko) 2019-08-07
AU2014203277B2 (en) 2017-04-06
JP2020040956A (ja) 2020-03-19

Similar Documents

Publication Publication Date Title
HUS1700036I1 (hu) Rekombináns, alfa-2,3- és alfa-2,6-szializációt tartalmazó FSH
EP2344648A4 (en) RECOMBINANT VECTORS
IL211762A0 (en) Pegylated opiods, compositions comprising the same and uses thereof
SI2356123T1 (sl) Piro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo(e)azuleni
AP2010005388A0 (en) Pupicidal and larvicidal composition.
ZA201005346B (en) 3,8-diaminotetrahydroquinoline derivative
IL207174A0 (en) Peptides, compositions, and uses thereof
HUE051918T2 (hu) Alfa 2,3- és alfa 2,6-szialilációt tartalmazó rekombináns FSH
GB0715213D0 (en) Igf-1
EP2384338A4 (en) GLP-1 ANALOGS AND THEIR APPLICATIONS
GB0808401D0 (en) Fsh
GB0813815D0 (en) Corcost Pre 1001,10
GB0809709D0 (en) Dunhill car,2093
GB0705503D0 (en) The buffer
GB0808811D0 (en) Algabe 2.1
GB0808847D0 (en) 10000001
GB0807658D0 (en) Sebaforce 2
GB0808958D0 (en) 10000004
GB0808845D0 (en) 10000003
GB0808846D0 (en) 10000002